[1]韩宇潇,李孟,谢春郁.旭痹舒汤联合来氟米特治疗寒湿痹阻型类风湿关节炎疗效观察[J].西部中医药,2024,37(01):145-149.[doi:10.12174/j.issn.2096-9600.2024.01.29]
 HAN Yuxiao,LI Meng,XIE Chunyu.Observation on Effects of Xubishu Tang Combined with Leflunomide in the Treatment of Rheumatoid Arthritis of Cold Dampness Obstruction Pattern[J].Western Journal of Traditional Chinese Medicine,2024,37(01):145-149.[doi:10.12174/j.issn.2096-9600.2024.01.29]
点击复制

旭痹舒汤联合来氟米特治疗寒湿痹阻型类风湿关节炎疗效观察
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年01期
页码:
145-149
栏目:
衷中参西
出版日期:
2024-01-15

文章信息/Info

Title:
Observation on Effects of Xubishu Tang Combined with Leflunomide in the Treatment of Rheumatoid Arthritis of Cold Dampness Obstruction Pattern
作者:
韩宇潇, 李孟, 谢春郁
黑龙江中医药大学附属第一医院/黑龙江中医药大学第一临床医学院,黑龙江 哈尔滨 150040
Author(s):
HAN Yuxiao, LI Meng, XIE Chunyu
First Affiliated Hospital/First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin 150040, China
关键词:
类风湿关节炎寒湿痹阻型血沉类风湿因子C反应蛋白旭痹舒汤来氟米特
Keywords:
rheumatoid arthritiscold dampness obstruction patternerythrocyte sedimentation raterheumatoid factorsCRPleflunomide
分类号:
R274.9
DOI:
10.12174/j.issn.2096-9600.2024.01.29
文献标志码:
B
摘要:
目的观察旭痹舒汤联合来氟米特治疗寒湿痹阻型类风湿性关节炎(rheumatoid arthritis,RA)的临床疗效。 方法将120例寒湿痹阻型RA患者经随机数字表法分为观察组和对照组各60例,对照组予来氟米特治疗,观察组予旭痹舒汤联合来氟米特治疗,比较两组患者临床疗效、主要症状与体征情况、体液免疫指标[血沉(erythrocyte sedimentation rate,ESR)、类风湿因子(rheumatoid factor,RF)、C反应蛋白(C-reaction protein,CRP)及免疫球蛋白G(immunoglobulin G,IgG)]、世界卫生组织生活质量测定量表简表(WHOQOL-BREF)评分及不良反应发生情况。 结果观察组总有效率为91.67%(55/60),高于对照组的76.67%(46/60)(P<0.05);治疗后观察组患者休息痛评分、晨僵时间、关节肿胀数、关节压痛数低于对照组,双手平均握力高于对照组(P<0.05);治疗后观察组ESR、RF、CRP、IgG水平低于对照组(P<0.05);治疗后观察组WHOQOL-BREF中周围环境、生理健康、社会关系、心理健康4个领域评分高于对照组(P<0.05);观察组不良反应发生率为6.67%(4/60),低于对照组的21.67%(13/60)(P<0.05)。 结论旭痹舒汤联合来氟米特能够改善寒湿痹阻型RA患者临床症状、体征以及体液免疫指标,有利于提高患者临床疗效及生活质量,并且不良反应发生率低。
Abstract:
ObjectiveTo discuss clinical effects of Xubishu Tang and leflunomide in the treatment of rheumatoid arthritis(RA) of cold dampness obstruction pattern. MethodsAll 120 RA patients were separated into the observation group and the control group using random number table method, the control group was treated by leflunomide, and the observation group by Xubishu Tang and leflunomide, to compare clinical effects, main symptoms and body signs, the indicators of humoral immunity including ESR, RF, CRP and IgG, WHOQOL scores and the incidences of adverse reaction between both groups. ResultsTotal effective rate of the observation group was 91.67%(55/60), higher than 76.67%(46/60) of the control group (P<0.05); after the treatment, rest pain score, morning stiffness time, number of swollen joints and number of joint tenderness of the observation group were lower than these of the control group, average grip strength of both hands higher than that of the control group (P<0.05); after the treatment,the levels of ESR, RF, CRP and IgG of the observation group were lower than these of the control group (P<0.05); after the treatment, the scores of surroundings, physical health, social relationships, mental health of WHOQOL-BREF of the observation group were higher than these of the control group (P<0.05); the incidence of adverse reaction of the observation group was 6.67%(4/60), lower than 21.67%(13/60) of the control group (P<0.05). ConclusionCompared with single use of leflunomide, its combination with Xubishu Tang could obviously improve clinical symptoms, body signs and the indicators of humoral immunity in RA patients, help improve the patients' clinical effects and quality of life, with low incidence of adverse reaction.

相似文献/References:

[1]马建辉,雷学峰,吕健△.中西医药物配合手法治疗类风湿性关节炎60例临床观察[J].西部中医药,2013,26(01):97.
 MA Jianhui,LEI Xuefeng,LV Jian.Integrative Medicine and Manipulation in the Treatment for 60 Cases of Rheumatoid Arthritis[J].Western Journal of Traditional Chinese Medicine,2013,26(01):97.
[2]张晓琴,何东初.复方玄驹胶囊联合甲氨蝶呤、来氟米特治疗类风湿关节炎40例[J].西部中医药,2012,25(05):78.
 ZHANG Xiao-qin,HE Dong-chu.Treatment of Rheumatoid Arthritis with Compound XuanJu Capsule combined with Methotrexate and Leflunomide: A Report of 40 Cases[J].Western Journal of Traditional Chinese Medicine,2012,25(01):78.
[3]王佳,王钢,王丽琴,等.秦艽醇提物治疗类风湿关节炎的实验研究[J].西部中医药,2015,28(07):11.
[4]刘佳,盛丽,张宝洲,等.类风湿性关节炎膝关节病变的高频超声评价[J].西部中医药,2015,28(10):134.
[5]陈慕芝,孙红艳,照日格图△.223例类风湿关节炎患者中医证候及实验室指标分析[J].西部中医药,2016,29(05):67.
 CHEN Muzhi,SUN Hongyan,ZHAORI Getu.The Analysis of Lab Indicators and TCM Patterns of 223 Patients with Rheumatoid Arthritis[J].Western Journal of Traditional Chinese Medicine,2016,29(01):67.
[6]李拥军,郭玉荣,尹智功,等.瑶药包热敷熨对类风湿关节炎患者血清白细胞介素1β及肿瘤坏死因子α的影响[J].西部中医药,2016,29(03):61.
 LI Yongjun,GUO Yurong,YIN Zhigong,et al.Influence of Yao Medicine Package Hot Ironing Therapy on IL-1β and TNF-α of the Patients with Rheumatoid Arthritis[J].Western Journal of Traditional Chinese Medicine,2016,29(01):61.
[7]徐萍,章鹏,于笑霞△.通痹胶囊治疗寒湿痹阻型类风湿性关节炎35例[J].西部中医药,2017,30(08):92.
 XU Ping,ZHANG Peng,YU Xiaoxia.TongBi Capsules in Treating 35 Cases of Rheumatoid Arthritis of Cold-dampness Impediment Pattern[J].Western Journal of Traditional Chinese Medicine,2017,30(01):92.
[8]何奕坤,杨光辉△,胥晓芳,等.类风湿关节炎继发肺间质病变的中医药治疗进展[J].西部中医药,2018,31(03):140.
 HE Yikun,YANG Guanghui,XU Xiaofang,et al.TCM Therapeutic Progress of Rheumatoid Arthritis/Interstitial Lung Disease[J].Western Journal of Traditional Chinese Medicine,2018,31(01):140.
[9]田雪梅,王海东,年芳红,等.武威汉代医简“瘀方”治疗中晚期痰瘀痹阻型类风湿关节炎验案举隅[J].西部中医药,2018,31(09):64.
 TIAN Xuemei,WANG Haidong,NIAN Fanghong,et al.Effective Cases of Treating Advanced Rheumatoid Arthritis of Phlegm-stasis Blocking Pattern by ″Stasis Prescription″ from Wuwei Medical Bamboo Slips in Han Dynasty[J].Western Journal of Traditional Chinese Medicine,2018,31(01):64.
[10]郭立霞,黄照国,闫恒志,等.清热利湿通络方联合西药治疗类风湿关节炎湿热痹阻证疗效观察[J].西部中医药,2018,31(07):83.
 GUO Lixia,HUANG Zhaoguo,YAN Hengzhi,et al.Clinical Observation on Heat-clearing Damp-eliminating Collateral-dredging Prescriptions Jointed with Western Medicine in Treating Rheumatoid Arthritis of Damp-heat Arthralgia Pattern[J].Western Journal of Traditional Chinese Medicine,2018,31(01):83.

备注/Memo

备注/Memo:
韩宇潇(1980—),女,硕士学位,主治医师。研究方向:风湿病的中西医结合治疗。E-mail:huligege745@163.com。黑龙江省中医药科研项目(XHY18-056)。
更新日期/Last Update: 2024-01-15